Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations
High BTLA transcript expression correlates with high transcript levels of PD-1 and CTLA-4 and with high levels of its ligand HVEM. These findings might support combining anti-PD-1 or anti-CTLA-4 therapy with anti-BTLA. BTLA expression varied across cancers and showed diverse coexpression patterns with other immune markers, suggesting that individual immunomic analysis is needed as part of a precision immunotherapy approach to understanding response and resistance.
Authors
- Taylor J. Jensen (ORCID: https://orcid.org/0000-0002-7206-7656)
- Daisuke Nishizaki (ORCID: https://orcid.org/0000-0002-6746-3224)
- Paul DePietro (ORCID: https://orcid.org/0000-0001-9072-0631)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Suzanna Lee (ORCID: https://orcid.org/0000-0002-9502-4907)
- Sarabjot Pabla (ORCID: https://orcid.org/0000-0002-7746-9144)
- Shumei Kato (ORCID: https://orcid.org/0000-0003-1193-1815)
- Sharon H. Choi (ORCID: https://orcid.org/0009-0008-8439-9288)
- Chinmayi Pandya (ORCID: https://orcid.org/0009-0001-7910-849X)
Institutions
- Medical College of Wisconsin (US)
- University of California San Diego (US)
- WIN Consortium
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1200/po-25-00304
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09